Inflectra is a biosimilar to Remicade [1]. Remicade is an infliximab-dyyb biosimilar [2].
What does "biosimilar" mean for Remicade?
A biosimilar is a biological product that is highly similar to a reference product and has no clinically meaningful differences in terms of safety, purity, and potency [3]. Inflectra, as a biosimilar to Remicade, offers an alternative treatment option for patients [1].
How does Inflectra compare to Remicade?
Inflectra (infliximab-dyyb) is approved for the same indications as Remicade (infliximab) [1][2]. Both drugs are used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [4][5]. Clinical studies have demonstrated that Inflectra has no clinically meaningful differences compared to Remicade [1].
When can biosimilars be approved?
The pathway for biosimilar approval is established by regulatory bodies. For a biosimilar to be considered interchangeable with its reference product, it must demonstrate that it can be substituted for the reference product without changing the treatment's effectiveness or safety profile [3].
Who makes Inflectra and Remicade?
Remicade is manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson [5]. Pfizer manufactures Inflectra, which was developed by Celltrion Healthcare [1][6].
What is the patent status for Remicade and its biosimilars?
Patent information for biologic drugs can be complex, with multiple patents covering various aspects of the product and its uses [7]. Information regarding the patent expiry of Remicade and the status of biosimilar patent litigation can be found on specialized databases [7]. DrugPatentWatch.com provides detailed patent information, including expiry dates and litigation status for pharmaceuticals [7].
Are there other biosimilars to Remicade?
Besides Inflectra, other infliximab biosimilars have been approved. For example, Renflexis (infliximab-dyyb) is another biosimilar to Remicade, also manufactured by Pfizer [6].
What are the potential benefits of biosimilars like Inflectra?
Biosimilars like Inflectra can increase competition in the market, potentially leading to cost savings for healthcare systems and patients [3]. They provide additional treatment options for patients who may benefit from similar therapeutic effects to the reference product [1].